

Supplementary Figure 1. Reverse cumulative distribution curves for the 13 serotypes included in PCV13, for the evaluable immunogenicity population (age ≥2 y). Vertical line at 0.35 µg indicates the threshold defined by the WHO to estimate efficacy of pneumococcal conjugate vaccines against invasive pneumococcal disease for infants [28], and is not a defined threshold of protection for other age groups or for this study population. conc.=concentration; PCV13=13-valent pneumococcal conjugate vaccine; WHO=World Health Organization.